MetTactics Limited

Our vision is to empower science to end cancer metastasis. Our mission is to provide a novel microfluidic platform for enabling anti-metastatic drug discovery and precision medicine. Our novel microfluidic device is the only platform that can recreate tumour microenvironment to enrich metastatic cells for research. Together with our data analytic software, our technology empowers scientists and researchers for faster drug development and data generation, and benefits cancer patients with more drugs that target metastasis. Our clinical test, using the genetic signature of metastatic cells to predict drug response, will also enable precision medicine for more effective cancer treatments.

A proprietary microfluidic platform to enrich truly metastatic cells of high clinical relevance for drug discovery and precision medicine

MetTactics’s products are: 1) a microfluidic device and a first-in-the-market data analytic software as RUO platform and 2) a clinical test for individualised precision medicine. We aim to help our customers to reduce R&D costs and enhance efficiency in identifying therapeutic targets and drug discovery. Our microfluidic device which enriches the truly metastatic cells, coupled with our advanced real-time cell tracking software, will bring a streamlined experiment pipeline for drug discovery. Our clinical test, which predicts the drug response of patients based on the genetic signature of their metastatic cells, can empower precision medicine to bring better treatment to patients.